On Thursday, December 16, Vaneltix entered into a Joint Development Agreement with Hyloris Pharmaceuticals NV, a Belgian pharmaceuticals company (“Hyloris”) with respect to Vaneltix’s Alenura™ product candidate. Under the Joint Development Agreement, Hyloris will provide certain funding for the development of our Alenura™ product candidate in return for a profit share if and when Alenura™ is commercialized. See [the link] below to Hyloris’ press release regarding the Joint Development Agreement.
There can be no assurance that the Joint Development Agreement will result in an approved product or, if Alenura™ is approved, that it will be accepted by the market or generate any level of revenues or profits. In addition, the foregoing may contain forward-looking statements. These statements may be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. Vaneltix has based these forward-looking statements on current expectations, assumptions, estimates and projections. While Vaneltix believes that these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond its control. Given these risks and uncertainties, investors and security holders are cautioned not to place undue reliance on such forward-looking statements. Vaneltix does not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments.